Gan & Lee Pharmaceuticals (603087.SH): The first subject in the United States Phase II clinical trial of Bovangluteptide (GZR18) injection completed dosing.

Gan & Lee Pharmaceuticals (603087.SH) announced that the company's self-developed Bo Fangelu peptide (research code: GZR18) injection is undergoing Phase II clinical trials in the United States, and recently successfully completed the dosing of the first trial subject. It is reported that Bo Fangelu peptide (research code: GZR18) injection is a GLP-1RA administered every two weeks, aimed at treating weight management in adults with type 2 diabetes and obesity/overweight individuals. Currently, a Phase II clinical trial for the indication of obesity/overweight is taking place in the United States, making it the world's first single-target GLP-1RA drug to be compared head-to-head with liraglutide for weight loss efficacy.